22 completed, 5 terminated, 2 unknown, 1 recruiting. 19 Phase 3, 8 Phase 2, 4 Phase 4, 2 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 19 | Completed 14, Terminated 5 |
| Phase 2 | 8 | Completed 6, Terminated 1, Unknown 1 |
| Phase 4 | 4 | Completed 3, Unknown 1 |
| Not applicable | 2 | Completed 1, Recruiting 1 |
| Phase 1 | 1 | Completed 1 |
Follow Lindner Center of HOPE: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| E-diary vs Paper Diary in Binge Eating Disorder The subject will complete e-diary for 2 weeks, complete paper diary for 2 weeks - Binge Eating Disorder | Not applicable | Recruiting | Lindner Center of HOPE | 40 | 2026-07-30 | 2026-07-20 |
| Solriamfetol in Binge Eating Disorder Solriamfetol, Placebo - Binge Eating Disorder | Phase 4 | Unknown | Lindner Center of HOPE | 64 | 2021-06-15 | 2023-03-08 |
| The Role of the Circadian System in Binge Eating Disorder Melatonin (3hrs before DLMO), Placebo (3hrs before DLMO), Morning light version 1 - Binge-Eating Disorder, Circadian Rhythm Disorders | Not applicable | Completed | University of Cincinnati | 84 | 2021-01-15 | 2026-08-21 |
| 8 Week Multi-site Study of MYDAYIS® for Bipolar Depression Mydayis Extended-Release Capsule, Placebo - Bipolar Depression | Phase 2 | Completed | Mayo Clinic | 74 | 2020-07-17 | 2025-08-12 |
| Spinal Cord Stimulation for the Treatment of Major Depressive Disorder Active transcutaneous spinal direct current stimulation, Sham transcutaneous spinal direct current stimulation - Major Depressive Disorder | Phase 1 / Phase 2 | Completed | University of Cincinnati | 20 | 2018-08-29 | 2024-12-27 |
| Saxenda® in Obese or Overweight Patients With Stable Bipolar Disorder (Investigator Initiated) LIRAGLUTIDE, Placebo - Bipolar Disorder, Obesity | Phase 2 | Completed | Lindner Center of HOPE | 60 | 2017-04-26 | 2025-03-12 |
| Lisdexamfetamine in Binge Eating Disorder (BED): fMRI Effects Lisdexamfetamine - Binge Eating Disorder | Phase 2 | Unknown | Lindner Center of HOPE | 40 | 2015-09-01 | 2016-01-20 |
| Phentermine/Topiramate Extended Release in Binge Eating Disorder (BED) PHEN/TPM ER (Qsymia®) - Binge Eating Disorder | Phase 2 | Completed | Lindner Center of HOPE | 10 | 2015-09-01 | 2016-09-20 |
| Ziprasidone in Bipolar Disorder With Comorbid Lifetime Panic or Generalized Anxiety Disorder(GAD) Ziprasidone, Placebo - Bipolar Disorder, Panic Disorder | Phase 4 | Completed | VA Palo Alto Health Care System | 49 | 2010-04-01 | 2025-04-08 |
| N-acetylcysteine in Bulimia Nervosa N-acetylcysteine NAC - NAC | Phase 2 / Phase 3 | Terminated | Lindner Center of HOPE | 11 | 2010-02-01 | 2013-05-10 |
| Efficacy Study of Lisdexamfetamine to Treat Binge Eating Disorder lisdexamfetamine, Placebo control - Binge Eating Disorder | Phase 3 | Completed | Lindner Center of HOPE | 50 | 2010-01-01 | 2016-07-15 |
| Adjunctive Lisdexamfetamine (LDX) in Bipolar Depression Lisdexamfetamine, Placebo control - Bipolar, Depression | Phase 3 | Terminated | Lindner Center of HOPE | 50 | 2010-01-01 | 2014-03-05 |
| Efficacy Study of Lisdexamfetamine to Treat Bipolar Depression Lisdexamfetamine, Placebo - Bipolar Depression | Phase 3 | Terminated | Lindner Center of HOPE | 25 | 2010-01-01 | 2015-09-02 |
| N-acetylcysteine in the Treatment of Bulimia Nervosa N-acetylcysteine - Bulimia Nervosa | Phase 3 | Terminated | Lindner Center of HOPE | 11 | 2009-12-01 | 2014-03-05 |
| Armodafinil in Binge Eating Disorder (BED) Armodafinil, Matching placebo - Binge Eating Disorder, Overweight | Phase 3 | Completed | Lindner Center of HOPE | 60 | 2009-11-01 | 2015-05-14 |
| A Study of Zonisamide to Prevent Olanzapine-Associated Weight Gain zonisamide, olanzapine, Zonisamide - Weight Gain | Phase 3 | Completed | Lindner Center of HOPE | 42 | 2008-01-01 | 2012-04-13 |
| Add-On Ramelteon in Bipolar I Disorder With Clinically Significant Sleep Disturbance Ramelteon, Placebo - Insomnia, Bipolar Disorder | Phase 3 | Terminated | Lindner Center of HOPE | 21 | 2007-12-01 | 2013-05-10 |
| Sodium Oxybate in the Treatment of Binge Eating Disorder Sodium Oxybate - Binge Eating Disorder | Phase 2 / Phase 3 | Completed | Lindner Center of HOPE | 15 | 2007-08-01 | 2011-06-22 |
| Acamprosate in the Treatment of Binge-Eating Disorder acamprosate, placebo - Binge Eating Disorder | Phase 2 / Phase 3 | Completed | Lindner Center of HOPE | 40 | 2007-04-01 | 2011-06-22 |
| Safety and Efficacy Trial of Olanzapine in Outpatients With Pathological Gambling olanzapine, sugar pill - Pathological Gambling | Phase 3 | Completed | Lindner Center of HOPE | 42 | 2007-02-01 | 2011-12-13 |
Showing 20 of 30. Sign in to see all of them.
Binge-Eating Disorder (12) · Bipolar Disorder (11) · Depression (4) · Obesity (3) · Anxiety Disorders (2) · Bulimia (2) · Generalized Anxiety Disorder (2) · Panic Disorder (2) · Bulimia Nervosa (1) · Chronobiology Disorders (1) · Depressive Disorder, Major (1) · Feeding and Eating Disorders (1) · Gambling (1) · Overweight (1) · Parasomnias (1)
Lisdexamfetamine Dimesylate (4) · Sugars (4) · Acetylcysteine (2) · Olanzapine (2) · Zonisamide (2) · Acamprosate (1) · Amphetamine (1) · Aripiprazole (1) · Atomoxetine Hydrochloride (1) · Dextroamphetamine (1) · Lamotrigine (1) · Levetiracetam (1) · Liraglutide (1) · Lithium Carbonate (1) · Melatonin (1)
United States (30)
Susan L McElroy, MD (5) · Susan L. McElroy, MD (5) · Anna Guerdjikova, PhD,LISW (1) · Francisco Romo-Nava, MD, PhD (1) · Francisco Romo-Nava, MD,PhD (1) · Lori Altshuler, MD (1) · Mark A Frye (1) · Paul Keck, Jr., MD (1) · Paul Keck, MD (1) · Susan L McEroy, MD (1) · Susan McElroy, MD (1) · Trisha Suppes, MD, PhD (1)
PMID 23265409, PMID 17194267, PMID 17229469, PMID 17388708, PMID 18251624, PMID 18339115, PMID 19042026, PMID 19357528, PMID 19963274, PMID 20209489, PMID 20361901, PMID 20861739, PMID 21080416, PMID 22367654, PMID 24345758, PMID 25340384, PMID 26011779, PMID 30013815, PMID 34610482, PMID 38123726, PMID 38227621
K23MH120503 (1), R01MH074707 (1)